Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dunelm posts modest FY growth, flags lack of sustained recovery

(Sharecast News) - Homewares retailer Dunelm reported modest full-year top-line growth on Monday but noted a cautious start to the new financial year, stating that while it was "pleased with early trading", it had yet to see signs of a sustained consumer recovery. Dunelm said revenues had risen 3.8% to £1.77bn in the year ended 28 June, while pre-tax profits ticked up 2.7% to £211.0m. Gross margins improved by 60 basis points to 52.4%, supported by disciplined buying and strong sell-through of seasonal ranges. Diluted earnings per share increased 3.2% to 76.8p.

The FTSE 250-listed firm said digital sales made up 40% of total revenues, up from 37% a year earlier, driven by growth in Click & Collect and enhanced online capabilities. However, net debt, on the other hand, increased to £102.0m from £55.6m, following investment in new stores, the acquisition of Home Focus in Ireland, and the purchase of the Designers Guild brand and archive.

Dunelm proposed a final dividend of 28.0p per share, taking its FY ordinary payout to 44.5p, up 2.3%. Including a special dividend of 35.0p paid in April, total dividends declared for the year were 79.5p per share.

However, Dunelm also stated that it although it has continued to gain share in a homewares and furniture market which grew slightly for the first time since FY22, it was yet to see signs of a wider consumer recovery so far in FY26, with consumer confidence remaining "lacklustre".

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.